334 replies to this topic

[ImmInst]

Anti-aging telomere science covered by new US patent
CosmeticsDesign.com USA - 1 hour ago

By Andrew McDougall, 17-Jan-2011 Geron Corporation has been granted a US patent for its technology to increase telomerase activity for the nutraceutical and cosmetics sector. Geron Corporation's ...

View the full article

[ImmInst]

Holzer Holzer & Fistel, LLC Announces Investigation Into Potential Claims For Breach Of Fiduciary Duties By Certain Officers And Directors of Geron Corporation
Reuters Key Development - 3 hours ago

View the full article

[ImmInst]

LOOK FOR SHARES OF GERON TO POTENTIALLY REBOUND AFTER YESTERDAY'S 4.08% SELL OFF (GERN)
Zacks.com - 1 hour ago

Jan 20, 2011 (SmarTrend® News Watch via COMTEX) -- Geron (NASDAQ:GERN) traded in a range yesterday that spanned from a low of $4.93 to a high of $5.22. Yesterday, the shares fell 4.08%, which ...

View the full article

[ImmInst]

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Geron Corporation
Reuters Key Development - Jan 22, 2011

View the full article

[ImmInst]

Geron Corporation (NASDAQ:GERN) moves 8.37 percent less than its 50-days Simple Moving Average
Chart Poppers - 10 hours ago

Geron Corporation (NASDAQ:GERN) reported the gain of 1.19% and closed at $4.89 whereas overall traded volume stood at 1.30 million shares for the day as compare to its average volume stood at 1.95 ...

View the full article

[ImmInst]

Top Biopharm Spotlight; Geron Review
Beacon Equity Research - 2 hours ago

Geron Corporation (NASDAQ: GERN) focuses in the development of biopharmaceuticals treatment for cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes ...

View the full article

[ImmInst]

Geron Downward Momentum Looks to Continue (GERN)
Benzinga - 2 hours ago

SmarTrend identified a Downtrend for Geron (NASDAQ: GERN) on December 08, 2010 at $4.96. In approximately 2 months, Geron has returned 3.9% as of today's recent price of $4.76. In the past 52 ...

View the full article

[ImmInst]

GERON DOWN 2%, SHARES SLIDE INTO THE RED (GERN)
Zacks.com - 6 hours ago

Jan 28, 2011 (SmarTrend® Spotlight via COMTEX) -- Geron (NASDAQ:GERN) is one of today's worst performing low-priced stocks, down 2% to $4.79 on 0.2x average daily volume. Approximately 283,000 ...

View the full article

[ImmInst]

Geron Downward Momentum Looks to Continue (GERN)
Benzinga - Jan 28, 2011

SmarTrend identified a Downtrend for Geron (NASDAQ: GERN) on December 08, 2010 at $4.96. In approximately 2 months, Geron has returned 3.9% as of today's recent price of $4.76. In the past 52 ...

View the full article

[ImmInst]

LOOK FOR SHARES OF GERON TO POTENTIALLY REBOUND AFTER YESTERDAY'S 3.27% SELL OFF (GERN)
Zacks.com - 3 hours ago

Jan 31, 2011 (SmarTrend® News Watch via COMTEX) -- Geron (NASDAQ:GERN) traded in a range yesterday that spanned from a low of $4.72 to a high of $4.92. Yesterday, the shares fell 3.27%, which ...

View the full article

[ImmInst]

Benzinga's Top Pre-Market NASDAQ Gainers (DEPO, NPSP, GERN, XNPT)
Benzinga - 12 hours ago

By Lisa Levin Depomed Inc (NASDAQ: DEPO) rose 31.41% to $8.20 in the pre-market session. The Food and Drug Administration (FDA) has approved DEPO's Gralise one-daily tablets for the treatment of ...

View the full article

[ImmInst]

Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors
Trading Markets - 1 hour ago

Corium International, Inc., a privately-held advanced transdermal drug delivery company, today announced the appointment of Dr. Bhaskar Chaudhuri and David L. Greenwood to the Board of Directors ...

View the full article

[ImmInst]

Geron Appoints David Greenwood President, Interim CEO And Director
TheStreet.com - 2 hours ago

By Business Wire 02/09/11 - 09:00 AM EST Geron Corporation (Nasdaq:GERN) today announced a new leadership structure that reflects the company's progression into mid-stage clinical development of ...

Geron Names CFO David Greenwood President, Interim CEO - Quick Facts - RTT News
Geron CEO steps down, an interim named - San Jose Business Journal
StreetInsider.com

View the full article

[ImmInst]

Geron Corporation Announces Management Changes
Reuters Key Development - 2 hours ago

View the full article

[ImmInst]

Geron Names David Greenwood as President, Interim CEO and Director
Trading Markets - 6 hours ago

Geron Corp. has announced a new leadership structure that reflects the company's progression into mid-stage clinical development of multiple therapeutic product candidates. In a release, the ...

Geron Appoints David Greenwood President, Interim CEO and Director - IEWY News

View the full article

[ImmInst]

Geron to Present at 13th Annual BIO CEO & Investor Conference
Business Wire - 6 hours ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (NASDAQ:GERN) today announced that David L. Greenwood, president and chief executive officer, will present an update of the company at 11:30 ...

Geron To Present At 13th Annual BIO CEO & Investor Conference - TheStreet.com

View the full article

[ImmInst]

Firm begins first human study using embryonic stem cell therapy
Catholic San Francisco - 3 hours ago

By Valerie Schmalz The first attempt to use therapies derived from human embryos on patients is coming to the San Francisco Bay Area as part of research that Menlo Park-based Geron Corp. hopes ...

View the full article

[ImmInst]

Ex-CEO Thomas Okarma departing Geron with $1.3 million, consulting deal, stock
Bizjournals.com - 5 hours ago

Former Geron Corp. President and CEO Thomas Okarma could receive up to $1.3 million, including $802,500 in severance pay, according to an agreement with the Menlo Park-based developer of stem cell ...

View the full article

[ImmInst]

Okarma takes $5M severance deal on his way out of Geron
FierceBiotech - 1 hour ago

Thomas Okarma will grab a severance package worth upwards of $1.3 million for his years of service as CEO of Geron, a stem cell therapy developer. The San Francisco Business Times reports that ...

View the full article

[ImmInst]

Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2010 Financial Results and Highlights
Business Wire - 1 hour ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) will announce its financial results for the fourth quarter and year ended December 31, 2010 on Thursday, February 24, 2011 ...

View the full article

[ImmInst]

Musician Spotlight: Melodramatics prepare to release first professionally recorded album
redding.com - 1 hour ago

In 2001, bassist Jesse Geron was in the band “4-Cents Short” and “things weren't going all that great.” He met two brothers who needed a bass player, scheduled a jam session, rocked some tunes and ...

View the full article

[ImmInst]

Geron Co. (GERN) Given "Neutral" Rating by Zacks Investment Research Analysts
American Banking News - 3 hours ago

Equities research analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Geron Co. (NASDAQ: GERN) in a research note to investors on Wednesday. The analysts currently ...

View the full article

[ImmInst]

Geron (GERN) Reports Q4 GAAP Loss of 59c
StreetInsider.com - 2 hours ago

StreetInsider.com provides up-to-the-minute active trading news and information. Only the most relevant news makes it through to our members, and only what you need to hear. Our articles are ...

View the full article

[ImmInst]

DIARY - U.S. Company Conference Call/Webcast for Feb 25, 2011
Reuters - 1 hour ago

DATE GMT SYMBOL COMPANY NAME AND PERIOD 25 Feb 13:00 (AMAG.O) Q4 AMAG Pharmaceuticals, Inc. Earnings Conf Call 25 Feb 13:30 (IPG) Q4 The Interpublic Group of Companies, Earnings Conf Call 25 Feb ...

View the full article

[ImmInst]

Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2010 Financial Results and Highlights
Live-PR.com - 2 hours ago

Geron Corporation (Nasdaq: GERN) will announce its financial results for the fourth quarter and year ended December 31, 2010 on Thursday, February 24, 2011, after the closing of the equity market ...

View the full article

[ImmInst]

Wider Q4 Loss at Geron
InvestorIdeas.com - 12 minutes ago

Geron Corporation (GERN - Analyst Report) posted a net loss of 24 cents per share in the fourth quarter of 2010, wider than the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss ...

View the full article

[ImmInst]

Geron Announces Preclinical Study Data of GRNCM1
Business Wire - 22 minutes ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced preclinical study data showing positive effects of GRNCM1, Geron's cardiomyocyte product derived from human ...

View the full article

[ImmInst]

Geron Co. (GERN) Posts Large Volume Increase, Hits $4.83
American Banking News - 49 minutes ago

Shares of Geron Co. (GERN) saw unusually high trading volume on Tuesday. Approximately 3,816,561 shares changed hands during mid-day trading, an increase of 207.49% from the previous session. The ...

View the full article

[ImmInst]

Geron's hESC derived GRNCM1 halts remodeling process and preserves cardiac function in acute heart damage
News-Medical.net - 2 hours ago

Geron Corporation (Nasdaq:GERN) today announced preclinical study data showing positive effects of GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells (hESCs), in a small ...

View the full article

[ImmInst]

Entrepreneur finds second life fighting aging
Crain's New York Business - 2 hours ago

The year 1995 was a turning point for Noel Patton. He sold the Fort Wayne, Ind.-based Patton Electric Co., which made electric fans and heaters, to appliance maker Rival Products for $30 million ...

View the full article